JP2013544802A - 炎症性疾患 - Google Patents
炎症性疾患 Download PDFInfo
- Publication number
- JP2013544802A JP2013544802A JP2013535515A JP2013535515A JP2013544802A JP 2013544802 A JP2013544802 A JP 2013544802A JP 2013535515 A JP2013535515 A JP 2013535515A JP 2013535515 A JP2013535515 A JP 2013535515A JP 2013544802 A JP2013544802 A JP 2013544802A
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- oil
- lipid
- alcohol
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1018289.7 | 2010-10-29 | ||
GBGB1018289.7A GB201018289D0 (en) | 2010-10-29 | 2010-10-29 | Treatment of respiratory disorders |
GB1113728.8A GB2487808A (en) | 2010-10-29 | 2011-08-10 | Oral adjuvant or formulation comprising a lipid and an alcohol |
GB1113728.8 | 2011-08-10 | ||
PCT/GB2011/052115 WO2012056251A1 (en) | 2010-10-29 | 2011-10-31 | Inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2013544802A true JP2013544802A (ja) | 2013-12-19 |
Family
ID=43401508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013535515A Pending JP2013544802A (ja) | 2010-10-29 | 2011-10-31 | 炎症性疾患 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2632431A1 (pt) |
JP (1) | JP2013544802A (pt) |
CN (1) | CN103282021A (pt) |
AU (1) | AU2011322255A1 (pt) |
BR (1) | BR112013010441A2 (pt) |
CA (1) | CA2816564A1 (pt) |
GB (2) | GB201018289D0 (pt) |
MX (1) | MX2013004817A (pt) |
RU (1) | RU2013124514A (pt) |
SG (1) | SG189551A1 (pt) |
WO (1) | WO2012056251A1 (pt) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016528279A (ja) * | 2013-08-19 | 2016-09-15 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 |
JP2016532701A (ja) * | 2013-08-19 | 2016-10-20 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する関節リウマチの予防または治療用組成物 |
JP2020530499A (ja) * | 2017-08-31 | 2020-10-22 | 漢義生物科技(北京)有限公司 | 抗インフルエンザ薬の調製におけるカンナビジオールの用途 |
WO2021132636A1 (ja) * | 2019-12-27 | 2021-07-01 | 特定非営利活動法人North East Japan Study Group | がん治療方法及び医薬 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
JP2014040396A (ja) * | 2012-08-23 | 2014-03-06 | Chemo-Sero-Therapeutic Research Institute | 脂質異常症治療薬を含有するアジュバント組成物 |
CN104098686B (zh) * | 2013-04-03 | 2016-03-23 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
CN103880924B (zh) * | 2012-12-21 | 2016-03-23 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
CN103880941B (zh) * | 2012-12-21 | 2016-02-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
BR112015015858B1 (pt) * | 2013-01-14 | 2023-02-28 | Infirst Healthcare Limited | Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica |
CN104098681B (zh) * | 2013-04-03 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
CN104098685B (zh) * | 2013-04-03 | 2016-03-23 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
CN104098671A (zh) * | 2013-04-03 | 2014-10-15 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
EP2986306A4 (en) * | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−10を使用する方法 |
CN103932977A (zh) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | 一种塞来昔布制剂的制备方法 |
CN103893171B (zh) * | 2014-04-19 | 2016-05-25 | 武汉胜达康生物科技有限公司 | 盐酸苄达明在制备治疗或预防流感病毒感染药物中的应用 |
AU2017424129B2 (en) * | 2017-07-18 | 2021-12-09 | Deyi Pharmarmaceutical Ltd. | Application of cannabidiol in treatment of pulmonary hypertension |
CN109419786B (zh) * | 2017-08-31 | 2021-04-30 | 汉义生物科技(北京)有限公司 | 大麻二酚在制备抗流感的药物中的用途 |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
CN111214467A (zh) * | 2020-03-05 | 2020-06-02 | 南京巴傲得生物科技有限公司 | 吲哚布洛芬在抵抗hmgb1促炎活性中的应用 |
CN111281973A (zh) * | 2020-03-31 | 2020-06-16 | 清华大学 | 含有trpv2激动剂的疫苗佐剂及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059626A (en) * | 1988-07-25 | 1991-10-22 | Applied Analytical Industries, Inc. | Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs |
JPH09504012A (ja) * | 1993-10-22 | 1997-04-22 | ヘクサル・ファルマ・ゲーエムベーハー | シクロスポリンA及びα−トコフェロールを含有する医薬組成物 |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
WO2008070950A1 (en) * | 2006-12-13 | 2008-06-19 | Laboratoires Mauves Inc. | Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms |
JP2013518869A (ja) * | 2010-02-05 | 2013-05-23 | バイオコピア リミテッド | 呼吸器疾患の治療 |
JP2014504629A (ja) * | 2011-02-04 | 2014-02-24 | バイオコピア リミテッド | 慢性炎症および炎症性疾患を治療するための組成物および方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US20080153894A1 (en) * | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
WO2008051186A2 (en) * | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
WO2010059717A2 (en) * | 2008-11-19 | 2010-05-27 | Merial Limited | Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
-
2010
- 2010-10-29 GB GBGB1018289.7A patent/GB201018289D0/en not_active Ceased
-
2011
- 2011-08-10 GB GB1113728.8A patent/GB2487808A/en not_active Withdrawn
- 2011-10-31 MX MX2013004817A patent/MX2013004817A/es unknown
- 2011-10-31 AU AU2011322255A patent/AU2011322255A1/en not_active Abandoned
- 2011-10-31 BR BR112013010441A patent/BR112013010441A2/pt not_active IP Right Cessation
- 2011-10-31 CA CA2816564A patent/CA2816564A1/en not_active Abandoned
- 2011-10-31 EP EP11784752.5A patent/EP2632431A1/en not_active Withdrawn
- 2011-10-31 JP JP2013535515A patent/JP2013544802A/ja active Pending
- 2011-10-31 CN CN2011800637601A patent/CN103282021A/zh active Pending
- 2011-10-31 SG SG2013033014A patent/SG189551A1/en unknown
- 2011-10-31 WO PCT/GB2011/052115 patent/WO2012056251A1/en active Application Filing
- 2011-10-31 RU RU2013124514/15A patent/RU2013124514A/ru not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059626A (en) * | 1988-07-25 | 1991-10-22 | Applied Analytical Industries, Inc. | Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs |
JPH09504012A (ja) * | 1993-10-22 | 1997-04-22 | ヘクサル・ファルマ・ゲーエムベーハー | シクロスポリンA及びα−トコフェロールを含有する医薬組成物 |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
WO2008070950A1 (en) * | 2006-12-13 | 2008-06-19 | Laboratoires Mauves Inc. | Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms |
JP2013518869A (ja) * | 2010-02-05 | 2013-05-23 | バイオコピア リミテッド | 呼吸器疾患の治療 |
JP2014504629A (ja) * | 2011-02-04 | 2014-02-24 | バイオコピア リミテッド | 慢性炎症および炎症性疾患を治療するための組成物および方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016528279A (ja) * | 2013-08-19 | 2016-09-15 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 |
JP2016532701A (ja) * | 2013-08-19 | 2016-10-20 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する関節リウマチの予防または治療用組成物 |
JP2020530499A (ja) * | 2017-08-31 | 2020-10-22 | 漢義生物科技(北京)有限公司 | 抗インフルエンザ薬の調製におけるカンナビジオールの用途 |
WO2021132636A1 (ja) * | 2019-12-27 | 2021-07-01 | 特定非営利活動法人North East Japan Study Group | がん治療方法及び医薬 |
Also Published As
Publication number | Publication date |
---|---|
WO2012056251A1 (en) | 2012-05-03 |
GB201018289D0 (en) | 2010-12-15 |
SG189551A1 (en) | 2013-06-28 |
EP2632431A1 (en) | 2013-09-04 |
GB2487808A (en) | 2012-08-08 |
BR112013010441A2 (pt) | 2016-08-09 |
CN103282021A (zh) | 2013-09-04 |
CA2816564A1 (en) | 2012-05-03 |
GB201113728D0 (en) | 2011-09-21 |
RU2013124514A (ru) | 2014-12-10 |
MX2013004817A (es) | 2013-07-03 |
AU2011322255A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013544802A (ja) | 炎症性疾患 | |
US11622997B2 (en) | Topical therapeutic formulations | |
JP6389190B2 (ja) | 固溶体組成物および慢性炎症における使用 | |
KR20110039249A (ko) | 지질 이상증의 개선 또는 치료약 | |
JP2013518869A (ja) | 呼吸器疾患の治療 | |
JP2014507429A (ja) | 心血管疾患の治療のための組成物および方法 | |
AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
JP2016514723A (ja) | アスタキサンチン抗炎症性相乗的組み合わせ | |
US20230082254A1 (en) | Topical therapeutic formulations | |
WO2017117268A1 (en) | Topical therapeutic formulations containing a calcium channel blocker, superoxide dismutase and emu oil | |
EP1734946B1 (en) | Punicic acid for use to enhance immune response and treating inflammatory bowel disease | |
RU2414221C2 (ru) | Фармацевтическая композиция на основе циклоферона местного и наружного применения для лечения гнойно-деструктивных поражений слизистой и кожи, общесистемных заболеваний при иммунодефицитных состояниях | |
CN103505414B (zh) | 丁苯酞滴鼻剂及其制备方法 | |
US20210251932A1 (en) | Method Of Treatment Of Obesity | |
JP2010229099A (ja) | 脂質異常症の改善または治療薬 | |
TW201105329A (en) | Medicament for the long term NSAID use | |
JP6100510B2 (ja) | 抗感冒剤 | |
WO2023192593A1 (en) | Buffering for non-alcoholic steatohepatitis and liver diseases | |
WO2021240540A1 (en) | Novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | |
JP2023534362A (ja) | カンナビノイドの使用および製剤 | |
KR20230052919A (ko) | 면역조절 제형 및 관련 방법 | |
TW201023868A (en) | Hypoglycemic activity of osthole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140826 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141203 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150721 |